ConductScience.org, home

Paper42318367

Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma.

Ibrahim M and 6 others. Mayo Clin Proc Innov Qual Outcomes, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma. Papers, record 42318367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42318367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Nivolumab-Associated Cardiac Manifestation of Cutaneous T-Cell Lymphoma in a Patient With Concurrent Renal Cell Carcinoma.
PubMed
Journal
Mayo Clin Proc Innov Qual Outcomes
PubMed
Year
2026
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ibrahim MMohamed
2Batra NNitya
3Adeoye OOluwatayo
4Monsanto MAMichael Acevedo
5Parent EEphraim
6Li DDavid
7Moustafa MAMuhamad Alhaj

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References15

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127269947Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.J Clin Oncol2016https://conductscience.org/library/papers/27269947PubMed
235784303Case Report: Primary Cardiac T-Cell Lymphoma With Complete Atrio-Ventricular Block Diagnosed by Endomyocardial Biopsy.Front Immunol2022https://conductscience.org/library/papers/35784303PubMed
332766875Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.Blood2020https://conductscience.org/library/papers/32766875PubMed
429143824PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.Nature2017https://conductscience.org/library/papers/29143824PubMed
540940933Immunotherapy-Associated Cardiotoxicity: Current Insights and Future Directions for Precision Cardio-Oncology.Cancers (Basel)2025https://conductscience.org/library/papers/40940933PubMed
640606990Cardiovascular adverse effects of immunotherapy in cancer: insights and implications.Front Oncol2025https://conductscience.org/library/papers/40606990PubMed
735559250Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.Front Pharmacol2022https://conductscience.org/library/papers/35559250PubMed
810583062Cardiac involvement and molecular staging in a fatal case of mycosis fungoides.Br J Dermatol1999https://conductscience.org/library/papers/10583062PubMed
932898250Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas.Blood Adv2020https://conductscience.org/library/papers/32898250PubMed
1017950613Mycosis fungoides.Crit Rev Oncol Hematol2008https://conductscience.org/library/papers/17950613PubMed
118284728Cardiogenic shock due to progression of cutaneous T-cell lymphoma.South Med J1994https://conductscience.org/library/papers/8284728PubMed
1235390769Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2022https://conductscience.org/library/papers/35390769PubMed
1334477818Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial.Blood Adv2021https://conductscience.org/library/papers/34477818PubMed
1433752450Clinical features of cardiac lymphoma: an analysis of 37 cases.J Int Med Res2021https://conductscience.org/library/papers/33752450PubMed
1531532724Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.J Clin Oncol2020https://conductscience.org/library/papers/31532724PubMed

Download CSV of references

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene
TNFRSF8943PubTator's text mininghttps://conductscience.org/library/genes/943NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42318367

GET https://conductscience.org/api/papers/v1/42318367/authors